Department of Internal Medicine, Inje University Seoul Paik Hospital, Seoul, Korea.
Division of Gastroenterology, Chung-Ang University College of Medicine, Seoul, Korea.
Korean J Intern Med. 2020 May;35(3):535-543. doi: 10.3904/kjim.2020.069. Epub 2020 Apr 29.
Acute pancreatitis is the most common and feared adverse event associated with performance of endoscopic retrograde cholangiopancreatography (ERCP). Unremitting effort has been made for over 40 years to minimize the frequency and severity of this complication. Recently, the use of rectal non-steroidal anti-inflammatory drugs (NSAIDs) have opened a new era for its prevention. This review focuses on the role of NSAIDs in pancreatitis, the pharmacokinetics of these agents, and summarizes the results of clinical trials with rectal NSAIDs alone and combination regimens in the prevention of post-ERCP pancreatitis.
急性胰腺炎是内镜逆行胰胆管造影术（ERCP）相关的最常见和最令人担忧的不良事件。40 多年来，人们一直在不懈努力，以尽量减少这种并发症的频率和严重程度。最近，直肠非甾体抗炎药（NSAIDs）的使用为其预防开辟了一个新时代。本综述重点讨论了 NSAIDs 在胰腺炎中的作用、这些药物的药代动力学，并总结了单独使用直肠 NSAIDs 和联合方案预防 ERCP 后胰腺炎的临床试验结果。
